Bristol/Roche Finally Start Combination Melanoma Trial
This article was originally published in The Pink Sheet Daily
Executive Summary
The drug makers, potential competitors, will study Bristol's CTLA-4 inhibitor Yervoy in combination with Roche's investigational BRAF inhibitor vemurafenib in metastatic melanoma.